Brad Rovin, MD, chief of nephrology at Ohio State University Wexner Medical Center, provides updates on the KDIGO guidelines for IgA nephropathy. The revised guidelines reflect new clinical…
After years of unexplained blood in her urine and a recent spike in protein levels during routine labs, this speaker was ultimately diagnosed with IgA nephropathy following extensive…
Sharon Adler, MD, professor of medicine at UCLA and investigator at The Lundquist Institute, explores the pathogenesis of IgA nephropathy, focusing on the four-hit hypothesis. She explains that…
Systemic mastocytosis with associated hematologic neoplasm (SM-AHN) presents unique diagnostic and treatment challenges. In this Medscape-certified activity, experts discuss the complex patient journey, from delayed diagnosis to individualized…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
Distinguishing indolent from advanced systemic mastocytosis is notoriously complex, even for seasoned clinicians. To simplify diagnosis, researchers developed a mathematical model using basic lab values, achieving 93% predictive…
In this episode of the Oncology Brothers podcast hosted by Rohit Gosain, MD and Rahul Gosain, MD speak to Jorge Cortes, MD, from the Georgia Cancer Center, joins…
Hematologist-oncologist and author Vinay Prasad, MD, MPH, dismantles claims that ivermectin and fenbendazole are miracle cancer cures, while also criticizing the FDA’s approval process for expensive anti-cancer drugs…
